Pharmaceutical

J&J-backed Bright Peak secures $90m to advance immunoconjugate programme

The funds will be used to advance PD1-IL18 immunoconjugate BPT567 into early-stage trials for solid tumours.

Jun 12, 2024 - 04:00
J&J-backed Bright Peak secures $90m to advance immunoconjugate programme
The funds will be used to advance PD1-IL18 immunoconjugate BPT567 into early-stage trials for solid tumours.
Read the original article

Tags:

Previous Article

UK clinical trial sector must address prolonged timelines, say experts

Next Article

Amphastar Pharmaceuticals gets grant for medication container assembly with cap ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Supreme Court halts Purdue bankruptcy plan; what to know about compounded obesity drugs

STAT+: Pharmalittle: Supreme Court halts Purdue bankrup...

Aug 11, 2023

Lilly strikes deal with QurAlis for preclinical ALS candidate

Lilly strikes deal with QurAlis for preclinical ALS can...

Jun 4, 2024

Listen: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech’s slump

Listen: Who discovered GLP-1? Plus: BrainStorm at the F...

Sep 28, 2023